Table 1.
Demographic and clinical profiles of the patients.
| Isolate | Age | Sex | Complaint | Sample | Carba-Penemase | MLST | Treatment | LOS (days) |
Prior Hospital-ization | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Kp1 | 62 | M | Acute right sided basal ganglia haemorrhage | TA | OXA-232 | ST-231 | Ceftriaxone 2g Q24H | 134 | No | Expired |
| Kp2 | 26 | F | Sepsis following Chronic renal failure | TA | OXA-232 | ST-231 | FOS 2g Q48H + MEM 500 mg Q24H + CL 9 MU loading dose then 2MU Q12H | 81 | Yes | Improved |
| Kp3 | 75 | F | Stroke | Urine | OXA-232 | Amikacin 15 mg/kg Q24 H (900 mg Q24H) | 13 | No | Improved | |
| Kp4 | 87 | M | Pyelonephritis | Urine | NDM-1 | Fosfomycin 6g Q6H (24 g per day) | 10 | No | Improved | |
| Kp5 | 79 | M | Pancreatic carcinoma Urinary incontinence | Urine | OXA-232 | ST-231 | None | 26 | No | Improved |
| Kp6 | 83 | M | Aspiration pneumonia, UTI, on suprapubic catheter | Urine | OXA-232 | ST-231 | MEM 1g Q12H + CL 9 mU loading dose then 2.5 mU Q12H | 12 | Yes | Expired |
| Kp7 | 56 | M | Pyelonephritis | Blood | OXA-48-like | FOS 6g 6H (total 24 g per day) + MEM 1g q8H | 14 | Yes | Improved | |
| Kp8 | 56 | M | CRE bacteremia | Urine | OXA-232 | ST-231 | FOS 8 q8H (total 24 g per day) + CL 9 mU loading dose followed by 4.5 mU Q12H + MEM 2g Q8H | 35 | Yes | Expired |
| Kp9 | 83 | M | Pyelonephritis | Urine | OXA-232 | FOS 6 gQ6H | 0 | Yes | Improved | |
| Kp10 | 76 | M | Bedsores | Wound | OXA-232 | ST-231 | None | 16 | Yes | Improved |
| Kp11 | 20 | M | Sepsis, Chronic renal failure | TA | NDM-1 | MEM 1g Q12H + CL 9 mU loading dose followed by 4mU Q8H | 19 | Yes | Expired | |
| Kp12 | 68 | M | Aspiration pneumonia | BW | OXA-232 | PTZ 4.5 g Q8H + TGC 100 mg loading dose then 50 mg Q12H | 12 | Yes | Improved | |
| Kp13 | 20 | M | Gastrointestinal basidiobolomycosis | Wound | OXA-232 | ST-395 | CL 9 mU loading dose then 4.5 mu Q12H + MEM 2g q8H + FOS 6g Q6H (total daily dose of 24 g) |
84 | No | Expired |
| Kp14 | 69 | M | Aspiration pneumonia | TA | OXA-232 | ST-395 | Tobramycin nebulization 300 mg Q12h , MEM 1g q8H + CL 9 mU loading dose then 4.5 mU Q12H |
44 | Yes | Improved |
| Kp15 | 49 | M | Pneumonia | BAL | OXA-232 | ST-231 | PTZ 4.5g Q8H | 10 | Yes | Expired |
| Kp16 | 65 | M | Metastatic gastric carcinoma | Urine | OXA-232+ NDM-5 |
ST-147 | PTZ 4.5 g Q8H | 8 | No | Improved |
| Kp17 | 79 | M | Acute Cystitis | Urine | OXA-48-like | Oral Fosfomycin 3g q3 days for 2 doses | - | Yes | Improved | |
| Kp18 | 39 | M | Haemorrhagic stroke, Bedsores | Wound | OXA-232 | ST-395 | PTZ 2.25 g Q8H | 126 | Yes | Expired |
Abbreviations: LOS: Length of stay, BW: Bronchial wash, TA: tracheal aspirate, M: male, F: female, AK: amikacin, CL: colistin, MEM: meropenem, SXT: cotrimoxazole, FOS: fosfomycin, PTZ: Piperacillin-tazobactam UTI: urinary tract infection, BAL: Bronchoalveolar Lavage.